Table 1.
Characteristics of patients with EGFR mutation‐positive NSCLC who received both first‐ and second‐line EGFR‐TKI
| No. | Sex | Age | PS | EGFR mutation | TKI sequence | Reasons for discontinuation (according to CTCAE v4.0) | Response to first TKI | TTF | Interval between TKIs | Response to second TKI | PFS for second TKI | PFS2 | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 49 | 1 | 19del | G (1) → E (2) | Hepatotoxicity (Gr3) | PR | 5.8 | 1.2 | SD | 2.1 | 9.1 | 30.3 |
| 2 | M | 81 | 1 | 19del | G (1) → E (2) | ILD (Gr3) | PR | 3.6 | 3.0 | PR | 1.8 | 8.4 | 8.4 |
| 3 | M | 79 | 0 | 19del | G (2) → E (3) | Hepatotoxicity (Gr3) | SD | 1.7 | 3.7 | PR | 9.8 | 15.2 | 25.9 |
| 4 | F | 71 | 0 | 19del | G (1) → E (2) | Hepatotoxicity (Gr4) | PR | 1.1 | 7.7 | SD | 19.1 | 27.9 | 58.3a |
| 5 | F | 83 | 0 | L858R | G (1) → E (2) | Hepatotoxicity (Gr2) | CR | 3.0 | 1.7 | CR | 9.3 | 14.0 | 19.8 |
| 6 | F | 75 | 1 | L858R | G (1) → E (2) | Hepatotoxicity (Gr2) | PR | – | 0.6 | SD | 2.4 | 17.3 | 31.2 |
| 7 | M | 63 | 0 | L858R | G (1) → E (2) | Hepatotoxicity (Gr3) | PR | 2.4 | 0.8 | SD | 30.1 | 33.4 | 53.3a |
| 8 | F | 59 | 0 | L858R | G (1) → E (2) | Hepatotoxicity (Gr3) | PR | 1.1 | 1.1 | PR | 12.5 | 14.7 | 32.8 |
| 9 | M | 56 | 0 | 19del | G (1) → E (2) | Hepatotoxicity (Gr3) | PR | 1.6 | 0.5 | PR | 45.8a | 47.9a | 47.9a |
| 10 | F | 62 | 0 | L858R | G (1) → E (3) | Hepatotoxicity (Gr4) | PR | 0.9 | 11.2 | PR | 8.9 | 20.9 | 40.1 |
| 11 | F | 84 | 0 | 19del | G (1) → E (2) | Hepatotoxicity (Gr2) | PR | 1.4 | 0.9 | SD | 32.8 | 35.2 | 46.8a |
| 12 | F | 69 | 1 | L858R | G (1) → E (2) | Hepatotoxicity (Gr4) | PR | 4.6 | 0.9 | SD | 1.6 | 7.1 | 20.6 |
| 13 | F | 67 | 0 | 19del | A (2) → G (3) | Paronychia, anorexia, diarrhea (Gr2) | PR | 2.3 | 1.0 | SD | 30.5 | 33.8 | 36.8a |
| 14 | F | 58 | 0 | 19del | A (1) → E (2) | ILD (Gr2) | PR | 4.1 | 2.3 | PR | 30.3a | 36.7a | 36.7a |
| 15 | F | 61 | 1 | L858R | G (1) → E (2) | Hepatotoxicity (Gr4) | SD | 1.6 | 1.4 | SD | 17.3 | 20.3 | 22.4 |
| 16 | F | 57 | 0 | 19del | A (1) → E (2) | ILD (Gr2) | SD | 1.5 | 1.1 | SD | 1.7 | 4.4 | 7.4 |
| 17 | F | 70 | 0 | 19del | G (1) → E (2) | Hepatotoxicity (Gr3) | PR | 0.8 | 2.0 | SD | 3.7 | 6.5 | 27.3a |
| 18 | F | 67 | 0 | 19del | E (1) → G (2) | Rash (Gr3) | PR | 6.8 | 0.4 | SD | 18.4 | 25.6 | 27.1a |
| 19 | M | 69 | 0 | L858R | G (1) → E (2) | Hepatotoxicity (Gr4) | SD | 1.1 | 1.5 | PR | 15.2 | 17.7 | 24.2a |
| 20 | M | 74 | 0 | L858R | G (1) → A (2) | Hepatotoxicity (Gr3) | SD | 1.4 | 1.5 | SD | 10.3a | 13.2a | 13.2a |
| 21 | M | 74 | 0 | 19del | G (1) → A (2) | Hepatotoxicity (Gr2) | PR | 1.6 | 0.6 | SD | 11.0a | 13.2a | 13.2a |
| 22 | F | 50 | 0 | L858R | A (1) → G (2) | Rash, anorexia, diarrhea (Gr2) | SD | 0.3 | 0.5 | PR | 6.2a | 7.0a | 7.0a |
A, afatinib; CR, complete response; CTCAE, common terminology criteria for adverse events; E, erlotinib; EGFR, epidermal growth factor receptor; F, female; Gr, grade; G, gefitinib; ILD, interstitial lung disease; L858R, exon‐21 mutation L858R; M, male; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; PS, performance status; SD, stable disease; TK1, tyrosine kinase inhibitor; TTF, time to treatment failure; 19del, exon‐19 deletion.
Unit of time is months.
Patients have continued the second EGFR‐TKI treatment, or back‐line therapy, and the latest follow‐up data were collected on 30 September 2017.